The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 42 | — | 20.1x | Near average | |
Growth | 81 | 98.0% | 5.6% | Above average | |
Quality | 36 | -47.0% | 7.6% | Near average | |
Safety | 91 | -2.8x | 0.4x | Above average | |
Capital Return | 34 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Ascendis Pharma A/S is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Ascendis Pharma A/S shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Ascendis Pharma stock saw stability in the average price target at 287.5 dollars, despite a new analyst joining the coverage to bring the total count to 6 analysts. This consistency reflects cautious optimism, as the stock is currently trading at 247.05 dollars, which is lower than even the lowest set price target (250 dollars), indicating a positive valuation gap from the analysts' perspective.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.